CI

At a glance

ClinicalIndex Comparison Record
Phase 3Active· 898 enrolled
Drug / intervention
Radiation Therapy +4 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03414970
NCT03414970Phase 3Active

RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation With Breast Reconstruction

Alliance for Clinical Trials in Oncology·interventional·Posted Jan 30, 2018·Updated Feb 24, 2026

In Brief

A Phase 3 clinical trial evaluating Radiation Therapy, Questionnaire Administration, and 3 other interventions for Ductal Breast Carcinoma and 8 related conditions. Active but no longer recruiting, targeting 898 participants across 859 sites in 2 countries.

Detailed Summary

This randomized phase III trial studies how well hypofractionated radiation therapy works in preventing recurrence in patients with stage IIa-IIIa cancer who have undergone mastectomy. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells that remain after surgery and have fewer side effects.

Study Details

Timeline

Phase 3Active
2018201920202021202220232024202520262027202820292030203120322033203420352036
First PostedJan 30, 2018
Enrollment StartMar 12, 2018
Primary CompletionFeb 1, 2024
Study CompletionAug 1, 2035
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 8.4 years ago

Interventions

Radiation Therapyradiation

Undergo RT

Questionnaire Administrationother

Ancillary studies

Quality-of-Life Assessmentother

Ancillary studies

Laboratory Biomarker Analysisother

Correlative studies

Hypofractionated Radiation Therapyradiation

Undergo hypofractionated RT